文献速递中医内科中药与中成药合理使用

降糖调脂方治疗2型糖尿病合并血脂异常的疗效与机制:临床试验方案

Efficacy and Mechanism of the Jiangtang Tiaozhi Recipe in the Management of Type 2 Diabetes and Dyslipidaemia: A Clinical Trial Protocol.
PubMed 文献 · Front Pharmacol · 2022-02-04

本研究为随机、阳性药平行对照、开放标签临床试验,计划纳入96例2型糖尿病合并血脂异常患者,随机接受降糖调脂方或二甲双胍治疗12周。主要结局为血糖和血脂有效控制率,次要结局包括体重、体质指数、腰围及中医症状评分,并通过16S rRNA测序和代谢组学探讨肠道菌群介导的机制。

要点

  • 降糖调脂方与二甲双胍对照,评估血糖血脂控制率。
  • 同步分析肠道菌群和代谢物,探索降糖调脂方作用机制。
  • 主要结局含糖化血红蛋白、空腹血糖、餐后2小时血糖、甘油三酯、低密度脂蛋白胆固醇。

核心结论

  • 该方案旨在验证降糖调脂方对2型糖尿病合并血脂异常的疗效,并探索肠道菌群代谢物介导的机制。

研究设计与样本

  • 随机、阳性药平行对照、开放标签临床试验,计划招募96例2型糖尿病合并血脂异常患者,随机分为降糖调脂方组或二甲双胍组,治疗12周。

关键数值与推荐

  • 主要结局为血糖和血脂有效控制率,以糖化血红蛋白、空腹血糖、餐后2小时血糖、甘油三酯和低密度脂蛋白胆固醇水平衡量。
  • 次要结局包括体重、体质指数、腰围变化及中医症状评分。
  • 将对粪便样本进行16S rRNA基因测序,并基于血液和肠道菌群样本进行代谢组学分析。
  • 将进行意向性分析、符合方案分析和安全性分析。

临床怎么用

  • 为2型糖尿病合并血脂异常患者使用降糖调脂方提供临床证据,并提示通过调节肠道菌群代谢物发挥作用的潜在途径。

局限性

  • 本研究为临床试验方案,尚未报告实际结果数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Type 2 diabetes mellitus (T2DM) complicated with dyslipidaemia is associated with a high risk of cardiovascular diseases. The Jiangtang Tiaozhi (JTTZ) recipe is a Chinese herbal formula that has been used to regulate the blood glucose and lipid levels for many years. Interestingly, a previous study has demonstrated its efficacy; however, the associated mechanism remains unclear. We hypothesised that the therapeutic effect of the JTTZ on patients with T2DM may be mediated by the modulation of metabolites secreted by the gut microbiota. This study aims to examine this mechanism. Methods and analysis: This study is a randomised, positive drug parallel-controlled, open-label clinical trial in patients with T2DM and dyslipidaemia. A total of 96 patients will be recruited and randomly assigned to treatment with JTTZ or metformin for 12 weeks. The primary outcome will be the rates of effectively regulated blood glucose and lipid levels (measured with the levels of glycated haemoglobin, fasting plasma glucose, 2-h plasma glucose, triglyceride, and low-density lipoprotein cholesterol). The secondary outcomes will be the changes in body weight, body mass index, and waist circumference and Traditional Chinese Medicine symptom scores. In addition, 16S rRNA gene sequencing will be performed on the gut microbiota obtained from faeces, and metabolomics analysis will be performed based on blood and gut microbiota samples. Intention-to-treat, per-protocol analysis and safety analysis will be performed. Clinical trial registration number: https://clinicaltrials.gov/ct2/show/NCT04623567.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Wu H, Fang X, Jin D, et al. Efficacy and Mechanism of the Jiangtang Tiaozhi Recipe in the Management of Type 2 Diabetes and Dyslipidaemia: A Clinical Trial Protocol. Front Pharmacol. 2022. PMID: 35185579. doi:10.3389/fphar.2022.827697

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。